ArticleJournal of clinical psychopharmacology
Understanding the Use of Atypical Antipsychotic Treatment for Major Depressive Disorder: An International Cross-Sectional Survey of Health Care Providers.
Article in Journal of clinical psychopharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to describe pharmacological prescribing patterns for major depressive disorder (MDD), particularly regarding the use of atypical antipsychotics (AAPs) for the treatment of MDD, and the underlying factors that may influence decision-making.
methodsAn electronic cross-sectional survey with 210 health care professionals (HCPs) involved in the treatment of MDD in 4 countries [United States (57), Canada (53), Brazil (39), Japan (61)] was conducted in May 2024 to July 2024.
resultsOf the total HCPs, 62.9% (n = 132) were psychiatrists, 31.9% (n = 67) primary care physicians or general practitioners, and 5.2% (n = 11) nurse practitioners or physician assistants. Selective serotonin reuptake inhibitors (SSRIs) were the most commonly prescribed first-line antidepressants across all countries surveyed. Regardless of disease severity, the first step for patients with inadequate response to the first antidepressant treatment was reported to be switching to another antidepressant (mild MDD: 66.7%, moderate MDD: 56.2%, severe MDD: 41.0%). Overall, SSRIs were the most common treatment class, typically augmented with AAPs, followed by serotonin-norepinephrine reuptake inhibitors. HCPs across the countries surveyed increasingly utilized augmentation with AAPs as the severity of MDD increased, with the severity of the current depressive episode and the number of prior antidepressants being the most important patient and treatment factors, respectively, in this decision. In addition, symptom domains, particularly underactive noradrenergic/norepinephrinergic activity and anxiety, were deemed crucial by HCPs in later treatment lines.
conclusionsThe study highlighted complex treatment paradigms in MDD and the need for alternative therapeutic strategies and more tailored options that specifically target receptor pharmacology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.